The study assessed the change in the integrated Alzheimer's Disease Rating Scale (iADRS) from baseline to 76 weeks in participants with low/medium tau levels and the overall population (low/medium and high tau levels), and secondary outcomes such as the Clinical Dementia Rating scale—Sum of Boxes (CDR‐SB) score.8 The gene discussed is MAPT; the disease is dementia.